The so-called "Right to Try" movement began as an effort to speed up the U.S. Food and Drug Administration’s drug approval process.
It’s based on the idea that terminally ill patients should be able to use experimental treatments or therapies that have completed some testing but that have not yet received FDA approval.
And now, supporters are urging officials to remove regulatory barriers in the age of COVID-19.
The Show spoke to Naomi Lopez, director of health care policy at the Goldwater Institute, which has long led the charge on "Right to Try."
